Clinical trials: Adolescent Behavior
Attention Deficit Hyperactivity Disorder
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in…
- Trial name
- NCT00723190
- Testing
- CLONICEL (Clonidine HCl sustained release)
- Where
- 27 sites in United States
- Volunteers
- 303 people
- Sponsor
- Shionogi
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Attention Deficit Disorder With Hyperactivity
NeuroLex EEG-Based ADHD Assessment Aid, Pivotal Study
The study will evaluate the effectiveness of a standardized EEG method with the intended clinical users in the intended clinical settings with the intended population (patients who would typically receive a clinician's evaluation…
- Trial name
- NEBA (NCT00595751)
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- Lexicor Medical Technology, LLC
Health Risk Behaviors
Sexually Active Adolescent Focused Education
SAAFE will be pilot tested in 2 geographically distinct areas (Washington, DC and Deep South) with 100 participants from each site to 1) primarily assess the efficacy of improved self-efficacy, knowledge about HIV/STIs and…
- Trial name
- SAAFE (NCT03646032)
- Testing
- SAAFE, Control
- Where
- 2 sites in United States
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Benten Technologies, Inc.
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
- Trial name
- NCT03247517
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 12 sites in United States
- Volunteers
- 310 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Sexual Behavior, Pregnancy Early
Evaluation of the Teen Outreach Program in Hennepin County, Minnesota
This study tested the extent to which TOP®, when replicated with fidelity, produced impacts on sexual risk-taking behaviors in the short term and the longer term.
- Trial name
- NCT02510209
- Testing
- Teen Outreach Program
- Where
- United States
- Volunteers
- 1,644 people, healthy volunteers welcome
- Sponsor
- Abt Associates
Bipolar Depression
Pediatric Bipolar Depression
The purpose of this study is to determine if quetiapine fumarate extended-release (quetiapine XR or SEROQUEL® XR) 150 to 300 mg/day taken by itself is effective and safe in treating children or adolescents aged 10 to 17 with…
- Trial name
- NCT00811473
- Testing
- Quetiapine XR
- Where
- 48 sites in United States, Colombia and 5 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca
Vaping, E Cig Use
A Hybrid Program to Prevent Substance Use Risk Among Upper Elementary School Students Using a Positive Youth Development Approach
The goal of this randomized controlled trial is to evaluate a psychosocial school-based hybrid intervention which includes traditional classroom sessions and online e-learning modules to reduce risk of vaping and prescription…
- Conditions
- Vaping, E Cig Use, Prescription Drug Misuse
- Trial name
- NCT07162155
- Testing
- School-based Hybrid Intervention to Prevent Vaping and Prescription Drug Misuse
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Christopher Williams
Attention Deficit Disorder With Hyperactivity
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.
- Trial name
- NCT00150592
- Testing
- SPD503 (Guanfacine HCl)
- Volunteers
- 182 people
- Sponsor
- Shire
Suicide, Mental Health Disorder
A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- ViraSafeRCT (NCT07348666)
- Testing
- ViraSafe: Treatment pushes, BRITE
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Ksana Health
Depression
Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression
The study is a pilot study where adolescents 12 - 18 years of age with mild to moderate depression will be randomized to receive either hypericum 250mg twice daily or fluoxetine 10mg daily increased to 20mg daily after 1 week and…
- Trial name
- NCT00557427
- Testing
- hypericum, fluoxetine
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rafa Laboratories
Disruptive Behavior Disorder
A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
The primary purpose of this study is to document the long-term safety of an oral formulation of risperidone in the treatment of children and adolescents with conduct and other disruptive behavior disorders.
- Trial name
- NCT00236470
- Testing
- risperidone
- Volunteers
- 232 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD
The purpose of this trial is to test the effectiveness of atomoxetine in treating symptoms of ODD in children with ADHD and ODD.
- Trial name
- NCT00191698
- Testing
- atomoxetine hydrochloride
- Where
- 16 sites in Australia, Belgium and 6 more
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
ADHD
Assessing a Wearable Digital Therapy for Youth With ADHD
The purpose of this study is to evaluate and compare three different investigational wearable digital interventions to determine if they are helpful for improving symptoms and functioning in children diagnosed with…
- Trial name
- NCT05710965
- Testing
- FRx-001, FRx-003, FRx-004
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Revibe Technologies
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
The study is designed to evaluate the efficacy and safety of SHP465 in the treatment of ADHD in children and adolescents (aged 6-17 years).
- Trial name
- NCT02466425
- Testing
- SHP465
- Where
- 36 sites in United States
- Volunteers
- 264 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity
An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride) in the Treatment of Adolescents With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the safety and effectiveness of CONCERTA® (methylphenidate hydrochloride, a central nervous system (CNS) stimulant) versus placebo for the treatment of Attention Deficit Hyperactivity…
- Trial name
- NCT00249353
- Testing
- methylphenidate hydrochloride
- Volunteers
- 220 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Conduct Disorder
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior.
- Trial name
- NCT00154362
- Testing
- Oxcarbazepine
- Volunteers
- 50 people
- Sponsor
- Novartis
Adolescent Pregnancy, Sexually Transmitted Diseases
A Parent Child Program to Prevent Adolescent Pregnancy
While the U.S. teen birth rate is currently at its lowest level, it remains high in relation to other industrialized countries and continues to be a public health concern due to health risks for teen mothers and their babies, and…
- Conditions
- Adolescent Pregnancy, Sexually Transmitted Diseases, Parental, Communication
- Trial name
- PPP_2 (NCT02333019)
- Testing
- Let's Talk About Sex, Websites; preventing teen pregnancy
- Where
- United States
- Volunteers
- 395 people, healthy volunteers welcome
- Sponsor
- Oregon Center for Applied Science, Inc.
Attention Deficit Disorder With Hyperactivity (ADHD)
Healing Minds II: Biofeedback, Breathing Practices, Nutrition and Exercise Counseling in Children and Adolescents With ADHD
The Pediatric Healing Minds II intervention includes a biofeedback component, breathing practices nutrition and exercise counseling.
- Trial name
- NCT07180602
- Testing
- Heart Math Biofeedback Breathing Practices, Nutrition Counseling combined with Exercise Counseling
- Where
- United States
- Sponsor
- Hoskinson Health and Wellness Clinic
ADHD
Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)
Assess the safety and efficacy of ADDERALL XR compared to placebo in the treatment of adolescents (aged 13-17) with ADHD. Subjects were assigned to one of two cohorts based on weight (<= 75 kg or > 75 kg).
- Trial name
- NCT00507065
- Testing
- Mixed salts of a single-entity amphetamine (ADDERALL XR)
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- Shire